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Namaqualand hip dysplasia (NHD), also referred to as Namaqua­
land spondyloepiphyseal dysplasia, is a mild form of spondylo­
epiphyseal dysplasia (SED) in which progressive arthropathy of 
the hip joint is a major manifestation. The disorder was initially 
documented in 45 members in five generations of a South African 
(SA) family with antecedents from Namaqualand, a region in the 
north­west of the country.[1] NHD differs from the classic forms of 
SED in terms of relatively normal stature and inconsistency of mild to 
moderate vertebral changes. The disorder mostly affects the femoral 
capital epiphyses of the hip joints and the vertebral bodies, and does 
not involve other systems (Fig. 1). The anatomical distribution of 
NHD is localised, with normal epiphyses and metaphyses throughout 
the remainder of the skeleton. Transmission of NHD is consistently 
autosomal dominant with variable expression. Onset is in childhood 
(average age of onset 10 years) with progressive disability. Both sexes 
are similarly affected. In childhood, the clinical and radiological 
manifestations are similar to those of Perthes disease and initial 
misdiagnosis is not unusual. As the orthopaedic management of 
these two disorders is very different, accurate diagnosis is essential. 
Linkage analysis in NHD revealed a locus that includes the collagen 
type II gene, COL2A1,[2] but the disease­causing variant has not been 
identified.
Objectives
The study aimed to address this deficiency by means of whole­exome 




Approval to undertake this study was obtained from the University 
of Cape Town’s Human Research Ethics Committee (ref. no. 
HREC 675/2015). Informed consent was obtained from a large 
multigenerational SA family presenting with NHD and unrelated 
individuals from the mixed­ancestry population who served as 
healthy controls (N=76). One affected male with a clear diagnosis of 
NHD was selected for WES. Pathogenicity of identified variants was 
confirmed with segregation analysis in the NHD family by selecting 
individuals for whom biological material was available; this group 
included 23 affected and 32 unaffected persons. The family, the NHD 
phenotype and their clinical diagnosis were previously described and 
documented for 45 affected individuals.[1­3] The cohort was extended 
to 55 individuals for the present study.
DNA extraction and quantification
Genomic DNA was extracted from peripheral blood using an adapted 
salting out method[4] and quantified with a Nanodrop ND­1000 
(Thermo Fisher Scientific, USA). The sample destined for WES was 
further quantified with a CFX96 real­time polymerase chain reaction 
(PCR) system (Bio­Rad, USA) and the TaqMan RNase P detection kit 
(MAN0007732 Rev. 2.0; Thermo Fisher Scientific), according to the 
manufacturer’s instructions. DNA was diluted accordingly.
Next-generation sequencing: Exomes
An Ion Torrent adapter­ligated library was generated with 1 µg 
genomic DNA using the Ion AmpliSeq Exome RDY kit with a 
SimpliAmp thermal cycler following the manufacturer’s protocol 
(MAN0010084 Rev. A.0; Thermo Fisher Scientific). Following AMPure 
bead purification (Beckman Coulter, USA), the concentrations 
of the adapter­ligated libraries were determined using the Bio­
Rad CFX96 real­time PCR system and the Ion Library TaqMan 
quantification kit (MAN0015802 Rev. B.0; Thermo Fisher Scientific) 
and diluted to 100 pM. The emulsion PCR, emulsion breaking and 
enrichment were performed using the Ion PI Hi­Q Chef 200 kit 
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on the Ion Chef liquid handler according 
to the manufacturer’s instructions (Thermo 
Fisher Scientific). An Ion PI chip kit v3 was 
templated with the Ion Chef and sequencing 
was performed on the Ion Proton. The 
Torrent Suite v4.0 (Thermo Fisher Scientific) 
was used to de­multiplex bar­coded reads 
and to generate run matrices, including 
chip­loading efficiency, coverage analysis 
and read quality. Raw signal data from 
the Ion Proton runs were processed using 
the Ion Torrent platform­specific pipeline 
to generate sequence reads, trim adapter 
sequences, filter, and remove poor signal­
profile reads and align sequences to the 
reference (UCSC hg19). Variant calling was 
performed on the Ion Reporter v5.2 cloud­
based software (Thermo Fisher Scientific) 
using the default workflow and parameters 
for this application.
The collagen genes, and specifically 
COL2A1, were prioritised for analysis 
based on linkage analysis results.[2] Variants 
were filtered according to their position, 
selecting only exonic and splice variants and 
excluding synonymous variants. Variants 
identified with WES were confirmed with 
direct cycle sequencing. Primers were 
designed using Primer3Plus[5] and standard 
conditions were used for PCR amplification 
of the relevant regions. Sequencing was 
performed with the BigDye Terminator 
v3.1 cycle sequencing kit according to the 
manufacturer’s instructions (pub 4337035 
Rev. D; Thermo Fisher Scientific) and 
capillary electrophoresis on a 3130xl Genetic 
Analyzer (Applied Biosystems, USA). 
Sequencing results were compared with the 
reference sequence for COL2A1 (Genbank 
accession NM_001844.4).
Genotyping
Genotyping was carried out in NHD family 
members and population controls using 
a KASP (kompetitive allele­specific PCR) 
genotyping assay (LGC Genomics, UK) on 
a Bio­Rad CFX96 real­time PCR system 
according to the instructions provided by 
the assay manufacturer. A KASP­on­demand 
assay was designed based on reference 
sequences. Alleles were assigned based 
on the clustering profiles obtained from 
controls for each genotype. Any ambiguities 
were resolved with direct cycle sequencing.
Results
WES identified one heterozygous non­
synonymous variant in the coding sequence 
of the COL2A1 gene, and its presence was 
confirmed by direct cycle sequencing. The 
variant, c.2014G>T in exon 31, results in 
an amino acid substitution, p.(Gly672Cys). 
Analysis with a KASP assay showed the 
heterozygous genotype to be present in 
23 NHD­affected individuals and absent 
in 32 unaffected individuals in this 
multigenerational SA family. The variant 
could not be detected in 76 unrelated controls 
from the same population group. The variant 
is also not present in the larger public genome 
databases (gnomAD, 1000 Genomes, ExAC 
and NCBI dbSNP), which confirms it to 
be an extremely rare variant. The above 
supports a pathogenic interpretation based 
on the guidelines published by the American 
College of Medical Genetics and Genomics 
(ACMG) (https://varsome.com/).[6]
Discussion
Various reports were published in the late 
1980s (1987 ­ 1990) that attributed SED and 
related disorders affecting the epiphyses to 
variants in the COL2A1 gene (MIM#108300). 
At least 460 COL2A1 pathogenic variants 
have been identified in up to 21 distinct 
disorders in this category.[7,8] Based on these 
reports, and also the localisation of type II 
collagen fibrils in the cartilaginous epiphyses, 
the locus was proposed as a likely candidate 
for NHD. Linkage studies confirmed that 
the link to the collagen type II locus was 
associated with the pathogenesis of NHD. [2] 
The current study, concerning 23 affected 
members of a large family with antecedents 
residing in Namaqualand, reports that the 
COL2A1 c.2014G>T; p.(Gly672Cys) variant 
is responsible for the NHD phenotype.
Namaqualand is a remote semi­desert 
region in the north­west of SA, which 
was relatively isolated a few decades ago. 
The population has genetic admixture 
from Khoisan, Cape Malay (Javanese 
and Sumatran), indigenous African and 
Western European sources. Genealogical 
studies have not determined the source 
of the mutation, be it from one of the 
ancestral groups or whether it has arisen 
more recently by spontan eous mutation. 
The functional significance of this variant 
was not in question, as both the position and 
the nucleotide change have been reported 
previously.[9,10]
The COL2A1 gene encodes the alpha 1 
chain of procollagen type II. Three pro­
alpha 1 chains twist together to form the 
procollagen molecule, which is processed 
into fibrils. The fibrils are cross­linked to 
form mature type II collagen fibres. Variants 
have been reported that are associated with 
a spectrum of rare, autosomal dominant 
conditions mainly characterised by skeletal 
dysplasia and short stature, collectively 
termed type II collagenopathies (Leiden 
Open Variation Database, http://databases.
lovd.nl/shared/genes/COL2A1; Human Gene 
Mutation Database, http://www.hgmd.cf.ac.
uk/ac/index.php). A common structural 
feature of collagen proteins is the presence 
of a triple helix. In COL2A1 the helical 
region is encoded by codons 201 ­ 1 214 
and is composed of a core repeat of three 
residues that all begin with a glycine (Gly­
X­Y). Most variants associated with type II 
collagenopathies are located in the region 
coding for the triple helix, with about a third 
replacing the glycine residue,[11] causing 
a dominant­negative effect that impairs 
homotrimer assembly and stability. Haplo­
insufficiency, on the other hand, results 
from nonsense substitutions and premature 
termination due to out­of­frame deletions 
or insertions. Nonsense­mediated RNA 
decay is initiated that results in reduced but 
normal synthesis of collagen, leading to a 
weakened matrix of articular cartilage. The 
effect is associated with milder phenotypes 
compared with those mediated by amino 
acid substitutions. This model is well 
established for type I collagenopathies, but 
Fig. 1. Anteroposterior radiograph of the hips in (A) an NHD-affected child aged 10 years showing 
fragmentation of the femoral capital epiphyses, and (B) an NHD-affected adult aged 36 years showing 
severe arthropathy. (NHD = Namaqualand hip dysplasia.)
59       January 2021, Vol. 111, No. 1
RESEARCH
less so for type II collagenopathies.[9] A previous study has shown 
that the position of amino acid substitutions affects the structure, 
thermostability and transport of mutant procollagen molecules and 
also the self­assembly of collagen fibrils.[12]
The COL2A1 c.2014G>T variant (codon 672) is located in the helical 
region of the protein, resulting in the substitution of a glycine residue 
for cysteine. The variant is classified as pathogenic based on the most 
recent ACMG guidelines. Three cases involving codon 672, causing 
glycine substitutions, have been reported. The variant was previously 
detected in a boy with Perthes disease­like presentation. [10] The affected 
child presented with bilateral dysplastic capital femoral epiphyses and 
normal height, but various additional skeletal abnormalities were 
observed. The initial presentation of NHD can mimic Perthes disease. 
NHD differs by being typically bilateral, and the involvement of the 
spine, femoral necks and acetabula is also distinctive. The second 
account is for a missense variant at the same position, but resulting 
in a different amino acid substitution, p.(Gly672Ser), reported in a 
Japanese female presenting as SED congenita with severe coxa vara 
(SEDC­S).[9] The category ‘SED’ represents a range of disorders, which 
may include NHD. The SEDC­S phenotype, however, has additional 
features, including short stature, which is a trademark of classic SED. 
It is relevant that the case reported by Nishimura et al.[9] had bone 
abnormalities that were evident at birth. Codon 672 has also been 
reported to be associated with Stickler syndrome type I (c.2015G>C, 
p.(Gly672Ala), rs794727546) (NCBI ClinVar). Unfortunately no 
clinical information was provided for this report.
It has been found that glycine to serine substitutions in COL2A1 
result in alternating zones that produce severer and milder phenotypes, 
whereas glycine to non­serine residues cause more severe phenotypes 
but never a severe and perinatal lethal condition. [13] Although 
more severe, cysteine introductions are still producing a broad 
spectrum of phenotypes, with either normal or short stature. In the 
current study, a cysteine substitution at codon 672 caused NHD, 
a milder phenotype than reported for a serine substation at the 
same position. [9] A remarkably different, more severe phenotype 
was also reported for the cysteine substitution at codon 672.[10] 
There is still no clear phenotype­genotype correlation for COL2A1 
variants, and the impact of variants is unpredictable. Different 
substitutions at the same position may produce phenotypes varying 
from mild to moderate to lethal, and similar or identical variants 
are related to conditions with different phenotypes.[7] The variable 
phenotypes observed for p.(Gly672X) support the notion of genetic 
or environmental modifiers that family members may share.
Clinical variability and phenotypic overlap in COL2A1­related 
disorders are commonly observed.[9,14] NHD is behaving as a typical 
autosomal dominant skeletal disorder, and severity is variable 
and age related. In general terms the condition often presents in 
early childhood with unilateral or bilateral pain in the hips and 
associated difficulty and discomfort in walking. The disorder is 
bilateral but not necessarily symmetrical, and no other joints are 
involved. By adulthood the severity of disability necessitates hip joint 
replacement in a proportion of affected individuals. Some degree of 
platyspondyly was observed (60%), and variable broadness of the 
femoral necks and flatness of the humeral heads were observed in 
20% of the individuals studied radiologically.[1] Inconsistent mild to 
moderate spinal malalignment and myopia in a small proportion of 
affected persons were the only other significant clinical problems.[2] 
Additional, mild abnormalities were observed that were considered 
insignificant at the time; however, the variable clinical presentation 
supports the notion of genetic and/or environmental modifiers and 
warrants further investigation. The large, clinically well­characterised 
NHD family is a valuable resource that could provide more insight 
into the mechanisms responsible for the variable expression observed 
in individuals with the variant.
Before NHD was clearly delineated, many affected family members 
had received a spurious diagnosis of Perthes disease. Currently, both 
Perthes disease and NHD have been accurately delineated, and they 
differ significantly in that Perthes disease is not familial, whereas in 
NHD all affected persons so far are members of the same extended 
family. NHD usually presents in early childhood, whereas Perthes 
disease is unusual before adolescence. There are no concomitants 
other than hip joint involvement in either of these conditions. The 
management of NHD is mainly orthopaedic and includes the provision 
of walking aids. Prosthetic joint replacement has proved to be effective 
in more severe cases.[3] Identification of the causative variant will 
permit presymptomatic diagnosis, which has practical significance 
for the clinical management of the asymptomatic potentially affected 
child. Although the COL2A1 gene has a large number of exons (54), 
it is small enough to consider screening with direct cycle sequencing. 
However, a next­generation sequencing (NGS) approach is justified 
as it allows for the simultaneous interrogation of a larger set of coding 
sequences utilising a targeted gene panel or WES. NGS is becoming 
a mainstream modality in the diagnosis of genetic collagen disorders. 
The predominant femoral head involvement in NHD is similar to 
that in other unique SA disorders of uncertain aetiology, such as 
Upington bone disease and Beukes arthropathy. The observation that 
the COL2A1 gene is involved in NHD has clear implications for the 
investigation of these conditions.
Conclusions
We identified a missense pathogenic variant in the COL2A1 gene in 
23 affected persons with NHD in a five­generation SA family. In view 
of the large size of this kindred, NHD is likely to be encountered in 
orthopaedic practice in this country. It is now possible to provide a 
molecular diagnosis before hip problems present in infancy and early 
childhood. COL2A1 variants are known to cause variable clinical 
expression. This large family is a valuable resource to further study 
modifiers of the clinical expression of NHD in individuals with a 
shared genetic background.
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